These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34862715)

  • 61. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dose finding studies for therapies with late-onset toxicities: A comparison study of designs.
    Barnett H; Boix O; Kontos D; Jaki T
    Stat Med; 2022 Dec; 41(30):5767-5788. PubMed ID: 36250912
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.
    Xue X; Foster MC; Ivanova A
    J Biopharm Stat; 2019; 29(4):625-634. PubMed ID: 31251112
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
    Phillips A; Mondal S
    Pharm Stat; 2023; 22(4):739-747. PubMed ID: 36669771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bayesian optimal interval design with multiple toxicity constraints.
    Lin R
    Biometrics; 2018 Dec; 74(4):1320-1330. PubMed ID: 29870069
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
    Lin X; Ji Y
    Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
    Yuan Y; Yin G
    Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose-finding designs for cumulative toxicities using multiple constraints.
    Lee SM; Ursino M; Cheung YK; Zohar S
    Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
    Ji Y; Wang SJ
    J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules.
    Günhan BK; Weber S; Friede T
    Stat Med; 2020 Nov; 39(27):3986-4000. PubMed ID: 32797729
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
    Mauguen A; Le Deley MC; Zohar S
    Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
    Zhao L; Lee J; Mody R; Braun TM
    Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
    Mu R; Xu G; Liu G; Pan H
    Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.